Publications
Cancer 2015: a longitudinal, whole of system study of genomic cancer medicine
Abstract
Genomic cancer medicine promises revolutionary change in oncology. The impacts of 'personalized medicine', based upon a molecular classification of cancer and linked to targeted therapies, will extend from individual patient outcomes to the health economy at large. To address the 'whole-of-system' impact of genomic cancer medicine, we have established a prospective cohort of patients with newly diagnosed cancer in the state of Victoria, Australia, about whom we have collected a broad range of clinical, demographic, molecular, and patient-reported data, as well as data on health resource utilization. Our goal is to create a model for investigating public investment in genomic medicine that maximizes the cost:benefit ratio for the Australian community at large.
| Type | Journal |
|---|---|
| Authors | Thomas, D.M.; Fox, S.; Lorgelly, P.K.; Ashley, D.; Richardson, G.; Lipton, L.; Parisot, J. P.; Lucas, M.; McNeil, J.; Wright M for the Cancer 2015 Investigators, .; |
| Responsible Garvan Author | Prof David Thomas |
| Publisher Name | DRUG DISCOVERY TODAY |
| Published Date | 2015-12-01 |
| Published Volume | 20 |
| Published Issue | 12 |
| Published Pages | 1429-32 |
| Status | Published in-print |
| DOI | 10.1016/j.drudis.2015.10.009. |
| URL link to publisher's version | http://www.ncbi.nlm.nih.gov/pubmed/26494144 |
| OpenAccess link to author's accepted manuscript version | https://publications.gimr.garvan.org.au/open-access/13076 |
